iSonea’s new asthma monitoring technology to feature at prestigious Las Vegas expo – Proactive Investors USA & Canada

iSonea's new asthma monitoring technology to feature at prestigious Las Vegas expo
Proactive Investors USA & Canada
iSonea (ASX: ISN, OTCQX: ISOAY) will give healthcare information technology leaders and professionals from around the globe a first look at its new asthma monitoring smartphone technology at a prestigious health information technology conference in the

and more »

View full post on asthma – Google News

iSonea’s new asthma monitoring technology to feature at prestigious Las Vegas expo – Proactive Investors Australia


Proactive Investors Australia

iSonea's new asthma monitoring technology to feature at prestigious Las Vegas expo
Proactive Investors Australia
iSonea (ASX: ISN, OTCQX: ISOAY) will give healthcare information technology leaders and professionals from around the globe a first look at its new asthma monitoring smartphone technology at a prestigious health information technology conference in the

View full post on asthma – Google News

IBM, Georgia Institute of Technology form pediatric data partnership – ZDNet (blog)

IBM, Georgia Institute of Technology form pediatric data partnership
ZDNet (blog)
This effort, dubbed One Million Healthy Children, will focus on children with diabetes, asthma and autism fist. The project includes Emory University, Children's Healthcare of Atlanta, Georgia Cancer Coalition and the Georgia Department of Community
IBM and Georgia Institute of Technology Partner on "One Million Healthy PR Newswire (press release)

all 11 news articles »

View full post on asthma – Google News

IBM and Georgia Institute of Technology Partner on “One Million Healthy … – PR Newswire (press release)

IBM and Georgia Institute of Technology Partner on "One Million Healthy
PR Newswire (press release)
The project, which includes partnerships with Emory University, Children's Healthcare of Atlanta, Georgia Cancer Coalition and the Georgia Department of Community Health, will focus initially on children suffering from diabetes, asthma and autism.

and more »

View full post on asthma – Google News

Latest Health and Wellness In-Car Technology from Ford to be Showcased Oct. 10 … – MarketWatch (press release)

Latest Health and Wellness In-Car Technology from Ford to be Showcased Oct. 10
MarketWatch (press release)
Ford is working with SDI Health and www.pollen.com to SYNC-enable its smartphone Allergy Alert app through AppLink, giving users voice-controlled access to the app that provides location-based day-by-day index levels for pollen; asthma, cold and cough

and more »

View full post on asthma – Google News

Gene Variant Could Explain Why Asthma Treatment Often Fails – MIT Technology Review


Los Angeles Times

Gene Variant Could Explain Why Asthma Treatment Often Fails
MIT Technology Review
A new study has revealed a genetic variant among asthma patients who don't respond well to steroid inhalers, the main treatment for the disease. The discovery could lead to a DNA test that could identify such patients early on,
Gene could explain why asthma treatments fail someReuters
What asthma means for those who have itKansas.com
Gene variant associated with reduced response to asthma inhalersLos Angeles Times
MedPage Today –MedCity News –HealthCanal.com
all 55 news articles »

View full post on asthma – Google News

Major US Allergy and Asthma Group Practice Adopts Aerocrine’s Technology

Allergy and Asthma Group Practice Adopts Aerocrine’s FENO Testing, Providing Personalized Asthma Management Technology

SOLNA, Sweden – 12 August 2011 – Aerocrine AB today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine’s FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis. Allergy & Asthma Specialists, P.C. is the largest group practice in the Philadelphia region specializing in allergic disease, asthma and immunology. Allergists use FENO to diagnose eosinophilic airway inflammation in patients with non-specific respiratory symptoms, to predict patient response to corticosteroid therapy, as well as to optimize dosing and assess adherence to anti-inflammatory therapy.

Allergy & Asthma Specialists, P.C. has eight locations in Philadelphia and surrounding suburbs. “We pride ourselves at providing our patients with the most up to date and comprehensive care,” said Dr. Robert Anolik, President of Allergy & Asthma Specialists, P.C. “Measurement of exhaled nitric oxide will enable us to provide optimal asthma management to our patients.”

“We are delighted to have this prestigious group of Allergy and Asthma Specialists on board with FENO testing, providing personalized asthma management”, said Kathy Hodgdon, Director of Sales & Marketing with Aerocrine. “In less than two minutes, this simple and inexpensive test makes it possible for physicians to better help patients living with asthma with appropriate therapy and disease control based on the patients’ individual needs.”

Asthma is a chronic inflammatory disease of the airways characterized by symptoms including wheezing and difficulty in breathing. The disease affects more than 300 million people around the world, of whom a significant number are children. Aerocrine’s founders made the original discovery that the levels of nitric oxide in exhaled breath, FENO, is elevated in patients with asthma. This has enabled a quick, effective and proactive method to measure the underlying inflammation in asthma, rather than being limited to reactively monitor its negative consequences in the form of symptoms and reduced lung function. The method has significant value in connection with diagnosis and choice of appropriate medication, as well as for the continuous management of asthma which is aimed at controlling the airway inflammation. Today, more than four million patient tests have been performed around the world using Aerocrine’s NIOX products.

For more information, contact:

Kathy Hodgdon, Director of Sales & Marketing, Aerocrine, Inc., telephone (314) 566-8546

Chip Neff, President, Aerocrine, Inc., telephone (919) 696-4267
Paul de Potocki, CEO, telephone: +46 8 629 07 80

For more information about Allergy & Asthma Specialists, please visit www.allergyandasthmawellness.com

About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 a.m. on August the 12th 2011.